CRO Simbec Research has appointed professor Trevor M. Jones non-executive chairman of the board of directors. Jones was formerly group R&D director of Wellcome and director general of the Association of the British Pharmaceutical Industry (ABPI).
Jones joins the board following the recent acquisition of the company through investment from the Wales Life Sciences Investment Fund (WLSIF) along with professor Chris Evans and Simbec's executive directors Howard Jenkins and Dr. Trevor Tanner. The acquisition, concluded in May, was the first investment of the newly created GBP100m WLSIF managed by Arthurian Life Sciences.
Jones has served on many committees, including the U.K. Government Medicines Commission, chair of the U.K. Genetics Advisory Board, the Council of King's College London and as a commissioner at The World Health Organization (WHO). He is a member of several European pharmaceutical company boards.